| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 62461 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
67 |
WYQ |
2024-12-19 |
| 62462 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
58 |
kx |
2024-12-19 |
| 62463 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
72 |
wyh |
2024-12-19 |
| 62464 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
76 |
zyl |
2024-12-19 |
| 62465 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
83 |
wyh |
2024-12-19 |
| 62466 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
105 |
zyl |
2024-12-19 |
| 62467 |
Gly3-vc-PAB-MMAE， ADC试剂 |
83 |
kx |
2024-12-19 |
| 62468 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
65 |
WYQ |
2024-12-19 |
| 62469 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
79 |
wyh |
2024-12-19 |
| 62470 |
Azido-PEG4-Val-Ala-PAB-PNP |
82 |
zyl |
2024-12-19 |
| 62471 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
69 |
h |
2024-12-19 |
| 62472 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
74 |
wyh |
2024-12-19 |
| 62473 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
67 |
WYQ |
2024-12-19 |
| 62474 |
MC-PBD， ADC试剂 |
76 |
kx |
2024-12-19 |
| 62475 |
Mal-Val-Ala-PAB的介绍 |
78 |
zyl |
2024-12-19 |
| 62476 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
64 |
h |
2024-12-19 |
| 62477 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
66 |
WYQ |
2024-12-19 |
| 62478 |
Arm-DOTA-B72.3 |
66 |
h |
2024-12-19 |
| 62479 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
83 |
zyl |
2024-12-19 |
| 62480 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
108 |
h |
2024-12-19 |
| 62481 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
71 |
kx |
2024-12-19 |
| 62482 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
73 |
h |
2024-12-19 |
| 62483 |
CAS: 863971-17-9，MC-Val-Cit-PAB-MMAF |
96 |
WYQ |
2024-12-19 |
| 62484 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
111 |
zyl |
2024-12-19 |
| 62485 |
DBCO-PEG4-vc-PAB-MMAE， ADC试剂 |
92 |
kx |
2024-12-19 |
| 62486 |
1884578-00-0，Boc-PEG4-Val-Ala-PAB-PNP，ADC定制 |
97 |
wyh |
2024-12-19 |
| 62487 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
66 |
h |
2024-12-19 |
| 62488 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
75 |
h |
2024-12-19 |
| 62489 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB，ADC定制 |
104 |
wyh |
2024-12-19 |
| 62490 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
80 |
h |
2024-12-19 |
| 62491 |
Azido-PEG4-MMAE，抗体药物偶联物（ADCs） |
108 |
WYQ |
2024-12-19 |
| 62492 |
1626359-62-3，SPDB-DM4， ADC试剂 |
68 |
kx |
2024-12-19 |
| 62493 |
Acid-PEG4-Val-Cit-PAB-MMAE，包含PEG链和MMAE等部分 |
74 |
WYQ |
2024-12-19 |
| 62494 |
cas:159857-70-2，MC-Val-Cit-Doxorubicin，ADC定制 |
95 |
wyh |
2024-12-19 |
| 62495 |
DOTA-(D)Phe(1)-Tyr(3) |
72 |
h |
2024-12-19 |
| 62496 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
112 |
zyl |
2024-12-19 |
| 62497 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
109 |
WYQ |
2024-12-19 |
| 62498 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
69 |
h |
2024-12-19 |
| 62499 |
CAS: 2762518-86-3 ，NHS ester-PEG4-Val-Cit-PAB-MMAE |
77 |
WYQ |
2024-12-19 |
| 62500 |
cas:2873452-49-2 ； MC-EVCit-PAB-MMAE，ADC定制 |
96 |
wyh |
2024-12-19 |
| 62501 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE，内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
119 |
WYQ |
2024-12-19 |
| 62502 |
cas:863971-24-8，Mc-MMAE ，马来酰亚胺基己酰-单甲基澳瑞他汀 E |
151 |
kx |
2024-12-19 |
| 62503 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
74 |
h |
2024-12-19 |
| 62504 |
cas:2259318-55-1 ， DBCO-(PEG2-VC-PAB-MMAE)2，ADC定制 |
82 |
wyh |
2024-12-19 |
| 62505 |
cas:1394238-91-5 Fmoc-Val-Ala-PAB |
106 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询